Chordate Medical presents interim report for Q3 2024 on Finwire TV
Kurs
-4,98%
Likviditet
0,08 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-05-23 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-05-21 | N/A | Årsstämma |
| 2025-03-28 | 08:30 | Bokslutskommuniké 2024 |
| 2025-01-28 | - | Extra Bolagsstämma 2025 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-08-29 | - | Split CMH 500:1 |
| 2024-05-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-20 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-03-22 | - | Bokslutskommuniké 2023 |
| 2024-01-26 | - | Extra Bolagsstämma 2024 |
| 2023-11-01 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-14 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-12-13 | - | Extra Bolagsstämma 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-30 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-26 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2022-04-25 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-10-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-05 | - | Extra Bolagsstämma 2021 |
| 2021-08-30 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2021-04-15 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Extra Bolagsstämma 2020 |
| 2020-08-07 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-24 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2020-04-23 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-11 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-27 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-10-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-20 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2017-04-19 | - | Årsstämma |
| 2017-02-10 | - | Bokslutskommuniké 2016 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Chordate Medical Holding (publ) released its interim report for Q3 2024 today at 08:30. At 13:00, the company invites you to a webcast presentation of the report with CEO Anders Weilandt on Finwire TV.
The presentation can be viewed through the following link: https://www.finwire.tv/webcast/chordate-medical/q3-2024/
Following the presentation, there will be a Q&A session where viewers can submit questions.
A recording of the presentation will be made available afterwards on the company’s website www.chordate.com and on Finwire TV’s YouTube channel.
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.